Nanomedicine and the COVID-19 vaccines
- PMID: 33247210
- PMCID: PMC7692425
- DOI: 10.1038/s41565-020-00820-0
Nanomedicine and the COVID-19 vaccines
Abstract
Two nanoparticle-based vaccines close to obtaining approval by the US Food and Drug Administration could represent a giant step in the fight against the COVID-19 pandemic.
References
-
- Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. Pfizerhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-an... (2020).
-
- Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study. Modernahttps://investors.modernatx.com/news-releases/news-release-details/moder... (2020).
-
- Expert reaction to Pfizer and BioNTech reporting interim results from phase 3 COVID-19 vaccine trial. Science Media Centrehttps://www.sciencemediacentre.org/expert-reaction-to-pfizer-and-biontec... (2020).
-
- Corum, J., Wee, S.-L. & Zimmer, C. Coronavirus vaccine tracker. The New York Timeshttps://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tra... (2020).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
